When the first vaccine against the virus that causes cervical cancer was launched last year, many women were excluded from being potential beneficiaries because of their age.
Gardasil, produced by US-based drug company Merck & Co, can only be administered to women up to the age of 26.
But health experts noted that it was also necessary to immunize older women especially since cervical cancer usually affects women when they are between 30 and 50 years old.
"The risk of cervical cancer increases with age, affecting women at the prime of their lives," said Diane Harper, an oncologist and professor at the Department of Women's and Gender Studies in Dartmouth College.
In the recent Asian launch in Manila of a second vaccine that has the potential to prevent cervical cancer in women over 30, Harper said the availability of such a medicine "marks the beginning of a new era in the future management of cervical cancer in the population of older women".
She said that based on studies, there would be a more significant reduction in the number of cervical cancer cases if women up to the age of 50 years were vaccinated against the HPV types that causes the disease.
Harper has worked with Belgium-based pharmaceutical company GlaxoSmithKline (GSK) to develop Cervarix, a vaccine that can be administered to women up to 50 years old to protect them against the HPV types that causes cervical cancer.